GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

Size: px
Start display at page:

Download "GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust"

Transcription

1 GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

2 Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent nomenclature is Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) 80% in small and large bowel, 20% in stomach and Pancreas.

3 Classification Various classification used to describe them Embryological (Fore gut, mid gut and hind gut) Behaviour (Carcinoid, Atypical carcinoid and neuroendocrine carcinoma) Histological (Well differentiated, moderately well differentiated and poorly differentiated)

4 CLASSIFICATION

5 Presentation Primary often small and asymptamatic Symptoms more often when metastasis occurs Can secrete variety of Hormones like Histamine, Gastrin, Somatostatin, Serotonin When symptomatic, symptoms depends upon location of tumour and anatomy of organ involved, like obstruction, perforation, bleeding etc.

6 Incidence of NETs Increasing Incidence per 100,000 - NETs All malignant neoplasms Neuroendocrine tumors Incidence per 100,000 All malignant neoplasm Yao JC et al. J Clin Oncol. 2008;26:

7 Investigation Identify the primary Depends upon symptoms Upper and lower GI endoscopy CT scan Fasting Gut hormones Extent of disease CT/MR scan MIBG scan Octreotide scan PET scan (Gallium) ECHO cardiography

8 Investigation Tumour markers Help in diagnosis Monitoring treatment Two commonly used markers are: Serum chromogranin A Urine 5 HIAA false +ve tryptophan/ serotonin-rich foods (bananas, avocados, plums, eggplant, tomatoes, plantain, pineapples, and walnuts)

9 Behavior of GI Carcinoids by Site

10 Behavior of GI Carcinoids by Site Foregut carcinoids Gastric (10%), duodenal (<5%). Generally low malignant potential

11 Behavior of GI Carcinoids by Site Foregut carcinoids Gastric (10%), duodenal (<5%). Generally low malignant potential Midgut carcinoids Ileal/Jejunal (25%). 60% malignant

12 Behavior of GI Carcinoids by Site Foregut carcinoids Gastric (10%), duodenal (<5%). Generally low malignant potential Midgut carcinoids Ileal/Jejunal (25%). 60% malignant

13 Behavior of GI Carcinoids by Site Foregut carcinoids Gastric (10%), duodenal (<5%). Generally low malignant potential Midgut carcinoids Ileal/Jejunal (25%). 60% malignant Appendiceal (40%). 1% malignant

14 Behavior of GI Carcinoids by Site Foregut carcinoids Gastric (10%), duodenal (<5%). Generally low malignant potential Midgut carcinoids Ileal/Jejunal (25%). 60% malignant Appendiceal (40%). 1% malignant

15 Behavior of GI Carcinoids by Site Foregut carcinoids Gastric (10%), duodenal (<5%). Generally low malignant potential Midgut carcinoids Ileal/Jejunal (25%). 60% malignant Appendiceal (40%). 1% malignant Hindgut carcinoids Rectal (20%), 15% malignant

16 Gastric Carcinoids

17 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis

18 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm)

19 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm) Type III. Gastrin-independent

20 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm) Type III. Gastrin-independent!! Sporadic

21 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm) Type III. Gastrin-independent!! Sporadic!! Account for 20% of gastric carcinoids

22 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm) Type III. Gastrin-independent!! Sporadic!! Account for 20% of gastric carcinoids!! Most aggressive

23 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm) Type III. Gastrin-independent!! Sporadic!! Account for 20% of gastric carcinoids!! Most aggressive!! Metastatic in 60% at resection

24 Gastric Carcinoids Type I! Atrophic Gastritis, Autoimmune Gastritis Type II! ZE, MEN (type 1) Clinical course is usually indolent (if <1 cm) Type III. Gastrin-independent!! Sporadic!! Account for 20% of gastric carcinoids!! Most aggressive!! Metastatic in 60% at resection!! May produce 5-HT and cause carcinoid! syndrome

25 Small Bowel Carcinoids

26 Small Bowel Carcinoids Most aggressive

27 Small Bowel Carcinoids Most aggressive May present with obstruction or abdominal pain due to intussusception, mechanical effect of the tumor, or mesenteric ischemia due to local fibrosis or angiopathy

28 Small Bowel Carcinoids Most aggressive May present with obstruction or abdominal pain due to intussusception, mechanical effect of the tumor, or mesenteric ischemia due to local fibrosis or angiopathy Carcinoid syndrome present in up to 10% patients

29 Small Bowel Carcinoids Most aggressive May present with obstruction or abdominal pain due to intussusception, mechanical effect of the tumor, or mesenteric ischemia due to local fibrosis or angiopathy Carcinoid syndrome present in up to 10% patients Multiple tumors in up to 30% of patients (worse prognosis)

30 Small Bowel Carcinoids Most aggressive May present with obstruction or abdominal pain due to intussusception, mechanical effect of the tumor, or mesenteric ischemia due to local fibrosis or angiopathy Carcinoid syndrome present in up to 10% patients Multiple tumors in up to 30% of patients (worse prognosis)!!

31

32 Appendiceal Carcinoids Typically benign course 1/300 appendices contains a carcinoid tumor Often found incidentally Goblet cell carcinoid variety makes serotonin and is more aggressive!!

33 Colon/Rectal Carcinoids Colon Usually right colon, particularly caecum Carcinoid syndrome is rare Rectal Carcinoids!! Size correlates with metastases: <1 cm - rare; > 2 cm (>70%) Carcinoid syndrome is rare Local excision of small carcinoids Extensive excision of larger (similar to adenocarcinoma) Controversial between 1cm and 2cm

34 Carcinoid Syndrome Manifests in the form of diarrhoea and flushing Occurs primarily with liver metastasis. Liver inactivates bioactive products; thus carcinoid syndrome does not happen in absence of liver mets (or non-gi carcinoids) Diversion of tryptophan to serotonin can result in tryptophan and nicotinic acid deficiency (pellagra) Serotonin causes diarrhea, stimulates fibroblast growth and fibrogenesis Serotonin does NOT cause flushing Flushing may be caused by histamine and kallikrein Most useful initial test is 24-hour urine 5-HIAA

35 Treatment General measure replacement of electrolytes and fluid lost in the course of diarrhoea; anti-ulcer medicines; avoiding food that precipitates symptoms etc. Surgery Resection of: Primary Appendectomy, right hemicolectomy, lobectomy Metastasis Ablation

36 Treatment Drug treatment Somatostatin receptor antagonist Short acting Long acting (Sandostatin LAR, Somatuline Autogel) Biologics Alpha interferone Chemotherapy Sunitinib Everolimus Cisplatin/Carboplatin + Etoposide. Streptozocin Adriamycin 5FU PRRT (Peptide Receptor Radionuclide Treatment)

37 Octreotide: Side effects Abdominal discomfort (29%) Flatulence (25%) Constipation (19%) Nausea (10%) Gall stones, biliary sludge, jaundice (62% over 18 months therapy) Hypoglycemia/Hyperglycemia Hypothyroid

38 PROMID: Octreotide LAR Slows Progression in Midgut NETs Proportion without progression TTP in Midgut NET Octreotide LAR vs placebo P = HR = 0.34 [95% CI: ] Time (months) Octreotide LAR (n = 42) Median 14.3 months Placebo: (n = 43) Median 6.0 months Based on conservative ITT analysis HR = hazard ratio. PROMID = Placebo-controlled prospective Randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic neuroendocrine MIDgut tumors; TTP = time to progression Rinke A et al. J Clin Oncol. 2009;27:

39 Other Trials CLARINET Study Assessing the effect of lanreotide autogel on tumour progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumours. >200 pts Awaiting analysis RADIANT 4 Double-blind, phase III study of Everolimus plus best supportive care Vs placebo + BSC in advanced NET GI/Lung origin

40 Cytotoxic Chemotherapy Streptozocin/Doxorubicin: 6-wk cycle Streptozocin 500 mg/m2 IV daily for 5 days Doxorubicin 50 mg/m2 IV days 1 and 22 (cumulative max dose of 500 mg/m2) 5FU/Doxorubicin/Streptozocin: 28 day cycle Streptozocin 400 mg/m2 IV days 1-5 5FU 400 mg/m2 IV bolus days 1-5 Doxorubicin 40 mg/m2 IV day 1 Temozolomide/Capecitabine: 28 day cycle Capecitabine 750 mg/m2 per dose PO BID, days 1-14 Temozolomide 200 mg/m 2 PO QD, days 10-14

41 PRRT Peptide Receptor Radionuclide Therapy (PRRT) Systemic radiotherapy Radiolabeled Somatostatin analogs Two potent agents 177 Lu-octreotate 90 Y-octreotide Available only in Few centre in UK

42 PRRT: Why to give? Study N Radiolabeled somatostatin analog Response (PR+CR) Symptom relief or reduction Median overall survival (Months) Bushnell, 2010 USA 90 90Y-edotreotide 4% >50% 26.9 Delpassand, 2008 USA 18 In-111 pentetreotide 11% N/A 13.3 Kwekkeboom 2008 Netherlands Forrer 2006 Switzerland 310 Lu-177-octreotate 30% N/A Y-DOTATOC 27% 83% N/A Anthony 2002 USA 26 In-111 pentetreotide 8% 62% 18 Schmidt et al, Oncogene, 2011

43 Any Questions?

NET und NEC. Endoscopic and oncologic therapy

NET und NEC. Endoscopic and oncologic therapy NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation

More information

MEDICAL MANAGEMENT OF METASTATIC GEP-NET

MEDICAL MANAGEMENT OF METASTATIC GEP-NET MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine

More information

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University

More information

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE

More information

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND

More information

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE

More information

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine

More information

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 Carcinoid Tumors: The Beginning and End Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 1 st described by Oberndofer(1907) Karzinoide = cancer like Arise from

More information

NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary)

More information

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,

More information

Surgical Therapy of GEP-NET: An Overview

Surgical Therapy of GEP-NET: An Overview Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior

More information

SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions

SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions MONDAY TEACHING SCOPE TODAYS SESSION Case 1: Basic Questions Case 2 Basic Questions Basic Theory Stuff: AJCC TNM + Stage Group for Carcinoid of the Appendix Management of Carcinoid of the Appendix (NCCN)

More information

2015: Year in Review Results of Recent Trials

2015: Year in Review Results of Recent Trials 2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research

More information

FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)

FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics

More information

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body

More information

Gastrinoma: Medical Management. Haley Gallup

Gastrinoma: Medical Management. Haley Gallup Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical

More information

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.

More information

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon

More information

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in

More information

An Overview of NETS. Richard R.P. Warner M.D

An Overview of NETS. Richard R.P. Warner M.D An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first

More information

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts

More information

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine

More information

Community Case. Saeed Awan R5

Community Case. Saeed Awan R5 Community Case Saeed Awan R5 18 year old presents to ER with history of pain right lower quadrant for three days. Nauseated, denies vomiting and bowel movements normal and no urinary complaint. Admitted

More information

WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer

WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers

More information

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some

More information

Lu 177-Dotatate (Lutathera) Therapy Information

Lu 177-Dotatate (Lutathera) Therapy Information Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine

More information

Evaluation and Management of Neuroendocrine Tumors

Evaluation and Management of Neuroendocrine Tumors Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017

More information

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Surgical Management of Neuroendocrine Tumors of the Gut Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Sites of GI Carcinoid Tumors Small intestine 44% Rectum

More information

Grade 2 Ileum NET with liver and bone metastasis

Grade 2 Ileum NET with liver and bone metastasis Grade 2 Ileum NET with liver and bone metastasis BERNARDO MARQUES ENDOCRINOLOGY DEPARTMENT PORTUGUESE INSTITUTE OF ONCOLOGY - COIMBRA April 2018, Lugano, Switzerland JPB, male, 67 years old April 2015

More information

Pathology testing and Neuroendocrine tumours (NETs)

Pathology testing and Neuroendocrine tumours (NETs) Pathology testing and Neuroendocrine tumours (NETs) NETs are probably far more common than we think. Most grow so slowly and produce such widely varied and non-specific symptoms, or no symptoms at all,

More information

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID Manoop S. Bhutani, MD, FASGE, FACG, FACP, AGAF, Doctor Honoris Causa Professor of Medicine Eminent Scientist of the Year 2008, World

More information

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust

More information

Recent developments of oncology in neuroendocrine tumors (NETs)

Recent developments of oncology in neuroendocrine tumors (NETs) Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in

More information

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,

More information

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man

More information

TUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca

TUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different

More information

Hot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ

Hot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid

More information

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm

More information

NEUROENDOCRINE TUMORS

NEUROENDOCRINE TUMORS NEUROENDOCRINE TUMORS A PRIMER FOR HEALTHCARE PROFESSIONALS Advocating the Right Team, the Right Treatment, at the Right Time for Neuroendocrine (NET) patients and physicians educating I funding I supporting

More information

Commonly Encountered Neuro-Endocrine Tumors of the Gut

Commonly Encountered Neuro-Endocrine Tumors of the Gut Commonly Encountered Neuro-Endocrine Tumors of the Gut Moderators: Giuseppe Aliperti, MD Steven Edmundowicz, MD Panelists Douglas O. Faigel, MD Professor of Medicine Department of Gastroenterology Oregon

More information

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy

More information

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED

More information

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs. GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March

More information

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different

More information

Sandostatin LAR. Sandostatin LAR (octreotide acetate) Description

Sandostatin LAR. Sandostatin LAR (octreotide acetate) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description

More information

Neuroendocrine Tumors

Neuroendocrine Tumors Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.

More information

Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms

Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Dr. Claudia LY WONG, Department of Surgery, Kwong Wah Hospital Joint Hospital Surgical Grand Round Presentation,

More information

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon

More information

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate

More information

Octreotide LAR in neuroendocrine tumours a summary of the experience

Octreotide LAR in neuroendocrine tumours a summary of the experience Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie

More information

Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic

More information

SURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece

SURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece SURGERY OF NETS Iakovos N Nomikos MD FACS Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece Epidemiology 5-fold increase in occurrence of NETS over past 30 years

More information

Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case

Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,

More information

Selection of Appropriate Treatment

Selection of Appropriate Treatment Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies

More information

Protocol for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: UPPER GI CANCER

Protocol for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: UPPER GI CANCER Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: UPPER GI CANCER Patient information given at each stage following agreed information pathway

More information

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)

More information

Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors Gastroenteropancreatic Neuroendocrine Tumors Mauro Cives, MD 1 and Jonathan R. Strosberg, MD 2 1 Assistant Professor, University of Bari, Department of Biomedical Sciences and Human Oncology, Bari, Italy;

More information

Rare GI Malignancies

Rare GI Malignancies Rare GI Malignancies Jordan Karlitz, MD Associate Professor of Medicine, Division of Gastroenterology Director, Hereditary GI Cancer and Genetics Program Tulane University School of Medicine Outline Gastrointestinal

More information

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό

More information

The PET-NET Study 2016 CNETS Grant Award

The PET-NET Study 2016 CNETS Grant Award The PET-NET Study 2016 CNETS Grant Award CANM Meeting April 21, 2017 Hagen Kennecke, MD, MHA, FRCPC Medical Oncology, BC Cancer Agency Associate Professor, University of British Columbia Raja Ampat, Indonesia

More information

Nuevas alternativas en el manejo de TNE avanzados

Nuevas alternativas en el manejo de TNE avanzados Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,

More information

Pharmacy Prior Authorization Somatostatin Analogs Clinical Guideline

Pharmacy Prior Authorization Somatostatin Analogs Clinical Guideline Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce

More information

Le target therapy nei Tumori Neuroendocrini

Le target therapy nei Tumori Neuroendocrini Le target therapy nei Tumori Neuroendocrini Take home messages Franco Grimaldi SOC Endocrinologia e Malattie del Metabolismo Nutrizione Clinica Azienda Ospedaliero-Universitaria Santa Maria della Misericordia

More information

NET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia

NET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia NET del pancreas ben differenziato: la terapia oncologica Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia Systemic treatment op:ons Somatosta:n analogues Interpheron

More information

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic

More information

Unexpected Findings at Endoscopy

Unexpected Findings at Endoscopy The Endoscopic Incidentaloma: What to Tell Your Patient t with Unexpected Endoscopic Findings: Gastric Intestinal Metaplasia, Silent Ileitis, Carcinoid David Greenwald, MD Montefiore Medical Center Albert

More information

Ongoing and future clinical investigation in GEP NENs

Ongoing and future clinical investigation in GEP NENs ESMO PRECEPTORSHIP PROGRAMME Multidisciplinary management, standards of care and future perspectives Lugano, Switzerland 13-14 April 2018 CHAIR: Nicola Fazio, Italy George Pentheroudakis, Greece Ongoing

More information

Chair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease

Chair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease Public slides Chair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease 2 nd Appraisal Committee meeting Committee

More information

Neuroendocrine & Carcinoid Tumors

Neuroendocrine & Carcinoid Tumors Neuroendocrine & Carcinoid Tumors Acknowledgment This slide set was medically reviewed by Dr. Yi-Zarn Wang, DDS, PC, MD, FACS in August 2018. Workshop Overview Introductions What Are Neuroendocrine Tumors

More information

GEP NET: algoritmo terapeutico. Dottor Nicola Fazio

GEP NET: algoritmo terapeutico. Dottor Nicola Fazio GEP NET: algoritmo terapeutico Dottor Nicola Fazio Basi per il trattamento Caratteristiche del paziente Caratteristiche del tumore P.S., sindrome, comorbidità Differenziazione, Ki-67 Imaging morfologico

More information

Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal

Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6

More information

New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer

New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant

More information

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 15 (2006) 681 685 Index Note: Page numbers of article titles are in boldface type. A Ablative therapy, for liver metastases in patients with neuroendocrine tumors, 517 with radioiodine

More information

Surgery for NET Challenges and specific aspects

Surgery for NET Challenges and specific aspects Surgery for NET Challenges and specific aspects Raymond Aerts, MD Department of Abdominal Surgery and Liver Transplantation University Clinics Leuven ESMO Preceptorship on GI neuroendocrine tumours (NETs)

More information

Pancreatic Neuroendocrine Tumours

Pancreatic Neuroendocrine Tumours UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior

More information

Recent Advances in Gastrointestinal Cancers

Recent Advances in Gastrointestinal Cancers Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:

More information

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review Gastrointestinal Cancer The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review MICHAEL MICHAEL, a ROCIO GARCIA-CARBONERO, b MATTHIAS M. WEBER, c CATHERINE

More information

Neuroendocrine Tumors

Neuroendocrine Tumors Carcinoid tumours: origin Neuroendocrine Tumors THE A, B,C s Bronchopulmonary system Other 8% 28% Carcinoid site Digestive system 64% 2.3 28 28.5 Other Colon and rectum Small intestine Colon, except appendix

More information

Schweizer Register für Neuroendokrine Tumore Le Registre Suisse des tumeurs neuroendocrines Registro Svizzero per i Tumori Neuroendocrini

Schweizer Register für Neuroendokrine Tumore Le Registre Suisse des tumeurs neuroendocrines Registro Svizzero per i Tumori Neuroendocrini Introduction Gastroenteropancreatic Neuroendocrine tumors (NETs) have a low incidence: overall more than 5/100 000. The significant growing incidence has been attributed to diagnostic tools (endoscopy,

More information

Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy

Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear

More information

A New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy

A New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi

More information

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic

More information

Peptic ulcer disease. Nomin-Erdene. D SOM-531

Peptic ulcer disease. Nomin-Erdene. D SOM-531 Peptic ulcer disease Nomin-Erdene. D SOM-531 Learning objectives Stomach gross anatomy PUD Epidemiology Pathogenesis Clinical manifestation Diagnosing Treatment Complicated ulcer disease Surgical procedures

More information

Case report. Kováčová Martina Comenius University in Bratislava Slovakia Faculty of medicine

Case report. Kováčová Martina Comenius University in Bratislava Slovakia Faculty of medicine Case report Kováčová Martina Comenius University in Bratislava Slovakia Faculty of medicine Past medical history 38 years old male patient No past medical or surgical history prior to presentation No medications

More information

Diagnosing and monitoring NET

Diagnosing and monitoring NET Diagnosing and monitoring NET Inaccurate or delayed diagnosis of neuroendocrine tumors (NET) is common, because many NET are small and asymptomatic. 1 When symptoms are present, they are usually nonspecific

More information

Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience

Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience RESEARCH ARTICLE Editorial Process: Submission:00/00/0000 Acceptance:00/00/0000 : A 15-Year Single Center Experience Abdullah Sakin 1 *, Makbule Tambas 2, Saban Secmeler 3, Orçun Can 3, Serdar Arici 3,

More information

Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.

Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine

More information

Diagnosis abnormal morphology and /or abnormal biochemistry

Diagnosis abnormal morphology and /or abnormal biochemistry Diagnosis abnormal morphology and /or abnormal biochemistry MEN 1 GEP Tumours Pancreatico-Nodal (-Duodenal) Affects 35-80% of MEN1 patients Functioning or non functioning Hyperplasia microadenoma macrotumours

More information

Prior Authorization Review Panel MCO Policy Submission

Prior Authorization Review Panel MCO Policy Submission Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

More information

Guide for patients, carers and doctors about Neuroendocrine (NET) Cancer

Guide for patients, carers and doctors about Neuroendocrine (NET) Cancer Guide for patients, carers and doctors about Neuroendocrine (NET) Cancer Guide for patients, carers and doctors about Neuroendocrine (NET) Cancer First Edition: 2015 The Unicorn Foundation PO BOX 384 Blairgowrie

More information

OVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS

OVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS OVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS Dr Christos G. Toumpanakis MD PhD FRCP FEBGH Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine

More information

Surgery for complications of advanced mid-gut carcinoid may be associated with prolonged survival: report of two cases

Surgery for complications of advanced mid-gut carcinoid may be associated with prolonged survival: report of two cases Surgery for complications of advanced mid-gut carcinoid may be associated with prolonged survival: report of two cases Lenka Humenska, StR Sam O Toole, FY1 Richard Guy, Consultant Department of General

More information

Principles of diagnosis, work-up and therapy The Gastroenterologist s role

Principles of diagnosis, work-up and therapy The Gastroenterologist s role Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Abdominal pain, in neuroendocrine tumor syndromes, 20, 25 26 Acromegaly, as neuroendocrine tumor presentation, 38 ACTH suppression studies,

More information

Impact of Functioning Metastatic Neuroendocrine Tumors

Impact of Functioning Metastatic Neuroendocrine Tumors Clinical Overview and Treatment Advances in Carcinoid Syndrome Sponsored by Lexicon Pharmaceuticals Impact of Functioning Metastatic Neuroendocrine Tumors Evaluation & Management 1 Presentation objectives

More information

Disclosure of Relevant Financial Relationships

Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available

More information

Peptide Receptor Radionuclide Therapy (PRRT) of NET

Peptide Receptor Radionuclide Therapy (PRRT) of NET Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None

More information

A case of persistent diarrhoea. Dr. Miles Levy, Dr. Jenny Prouten, Priya Jalota

A case of persistent diarrhoea. Dr. Miles Levy, Dr. Jenny Prouten, Priya Jalota A case of persistent diarrhoea Dr. Miles Levy, Dr. Jenny Prouten, Priya Jalota Presentation 58 year old male with 3/12 history of persistent change in bowel habit following trip to India in January 2012

More information